Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Drug regulator announces bisphosphonates safety review

By Lilian Anekwe

The European drug regulator has announced an investigation into a link between the prescribing of bisphosphonates for osteoporosis and stress fractures.

The European Medicines Agency has been alerted to suggested class-related increase in atypical stress fractures, it announced last week.

The agency has asked its Committee for Medicinal Products for Human Use to investigate a ‘possible increased risk of atypical stress fractures in patients taking bisphosphonate-containing medicines for the treatment and prevention of bone disorders'.

This follows an EMA review of published literature and post-marketing reports, which suggested that atypical stress factures might be a class effect of bisphosphonates.

A warning about atypical stress fractures of the proximal femoral shaft has been included in the product information for alendronate-containing medicines across Europe, since a review in 2008.

A statement from the EMA said the review will look at ‘all available data thoroughly, including published data, non-clinical and clinical data and post-marketing reports, to clarify whether atypical stress fractures are a class effect of bisphosphonates, and will assess their impact on the balance of risks and benefits of these medicines'.

The EMA is investigating alendronate-containing medicines

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say